The clinical-grade iExosomes were tested in multiple in vitro and in vivo studies to confirm suppression of oncogenic KRAS and an increase in the survival of several mouse models with pancreatic cancer (106, 107). The gene discussed is KRAS; the disease is familial pancreatic carcinoma.